HY-138616 Search Results


gw7647  (MedChemExpress)
94
MedChemExpress gw7647
A , Cell viability was assessed in CAOV3 cells treated with 10µM erastin, 2% ascites, and 1mM bezafibrate (PPARα agonist), 0.8mM C-75 Trans (FASN inhibitor), 100µM Sulfo-N-succinimidyl oleate (SSO) (CD36 inhibitor), 50µM MF-438 (SCD1 inhibitor), and 80µM BMS-309403 (FABP4 inhibitor) ( n provided in panel, 48 hours). B-D , ( B ) TYKNU, ( C ) TOV21G, and ( D ) TOV112D cells were treated with 10µM erastin, 2% ascites, and 200µM ( B , D ) or 400µM ( C ) bezafibrate ( n =3, 48 hours). E-F , CAOV3 cells were treated with ( E ) 5µM IKE or ( F ) 2.5µM JKE-1674, 2% ascites, and 200µM bezafibrate ( n =3, 48 hours). G-H , CAOV3 cells were treated with ( G ) 10µM erastin, 2% ascites, 200µM bezafibrate, 60µM fenofibrate, 500µM ciprofibrate, or ( H ) 250nM <t>GW7647</t> ( n provided in panel, 48 hours). I , CAOV3 cells were transduced with a PPRE-luciferase reporter constructed and treated with 2% ascites in the presence or absence of 800µM bezafibrate. Luminescence was measured after 1mM D-luciferin addition ( n =3, 16 hours). J , The log-transformed changes in CAOV3 PPARA target DEGs after 10% ascites exposure ( n =3, 16 hours, adj. P =0.01). The target genes were determined via the PPARGene database ( http://www.ppargene.org/index.php ), which provides all verified PPARα target genes. K , ascites from 7-week-old NSG mice were collected after IVIS imaging. All ascites was pooled together and 8% was added to CAOV3 cells with or without 2.5µM JKE-1674 treatment to assess ferroptosis protection ( n =3). Cell viability tests were measured with the CellTiter-Glo® assay. All data represent mean ± s.d. Statistical significance was assessed using correlated-samples one-way (ANOVA), and multiple comparisons were adjusted using Holm-Šídák’s method. All statistical tests were two-tailed where applicable.
Gw7647, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gw7647/product/MedChemExpress
Average 94 stars, based on 1 article reviews
gw7647 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
ai 10 47  (MedChemExpress)
94
MedChemExpress ai 10 47
A , Cell viability was assessed in CAOV3 cells treated with 10µM erastin, 2% ascites, and 1mM bezafibrate (PPARα agonist), 0.8mM C-75 Trans (FASN inhibitor), 100µM Sulfo-N-succinimidyl oleate (SSO) (CD36 inhibitor), 50µM MF-438 (SCD1 inhibitor), and 80µM BMS-309403 (FABP4 inhibitor) ( n provided in panel, 48 hours). B-D , ( B ) TYKNU, ( C ) TOV21G, and ( D ) TOV112D cells were treated with 10µM erastin, 2% ascites, and 200µM ( B , D ) or 400µM ( C ) bezafibrate ( n =3, 48 hours). E-F , CAOV3 cells were treated with ( E ) 5µM IKE or ( F ) 2.5µM JKE-1674, 2% ascites, and 200µM bezafibrate ( n =3, 48 hours). G-H , CAOV3 cells were treated with ( G ) 10µM erastin, 2% ascites, 200µM bezafibrate, 60µM fenofibrate, 500µM ciprofibrate, or ( H ) 250nM <t>GW7647</t> ( n provided in panel, 48 hours). I , CAOV3 cells were transduced with a PPRE-luciferase reporter constructed and treated with 2% ascites in the presence or absence of 800µM bezafibrate. Luminescence was measured after 1mM D-luciferin addition ( n =3, 16 hours). J , The log-transformed changes in CAOV3 PPARA target DEGs after 10% ascites exposure ( n =3, 16 hours, adj. P =0.01). The target genes were determined via the PPARGene database ( http://www.ppargene.org/index.php ), which provides all verified PPARα target genes. K , ascites from 7-week-old NSG mice were collected after IVIS imaging. All ascites was pooled together and 8% was added to CAOV3 cells with or without 2.5µM JKE-1674 treatment to assess ferroptosis protection ( n =3). Cell viability tests were measured with the CellTiter-Glo® assay. All data represent mean ± s.d. Statistical significance was assessed using correlated-samples one-way (ANOVA), and multiple comparisons were adjusted using Holm-Šídák’s method. All statistical tests were two-tailed where applicable.
Ai 10 47, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ai 10 47/product/MedChemExpress
Average 94 stars, based on 1 article reviews
ai 10 47 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
dgtp-13c10,15n5  (MedChemExpress)
N/A
dGTP-13C10,15N5 (2'-Deoxyguanosine-5'-triphosphate-13C10,15N5) dilithium is 13C and 15N-labeled dGTP (HY-138616). dGTP (2'-Deoxyguanosine-5'-triphosphate), a guanosine nucleotide, can be used in deoxyribonucleic acid synthesis. Guanosine nucleotides (GDP, GTP, dGDP, and dGTP) are highly susceptible to oxidative damage to
   Buy from Supplier

Image Search Results


A , Cell viability was assessed in CAOV3 cells treated with 10µM erastin, 2% ascites, and 1mM bezafibrate (PPARα agonist), 0.8mM C-75 Trans (FASN inhibitor), 100µM Sulfo-N-succinimidyl oleate (SSO) (CD36 inhibitor), 50µM MF-438 (SCD1 inhibitor), and 80µM BMS-309403 (FABP4 inhibitor) ( n provided in panel, 48 hours). B-D , ( B ) TYKNU, ( C ) TOV21G, and ( D ) TOV112D cells were treated with 10µM erastin, 2% ascites, and 200µM ( B , D ) or 400µM ( C ) bezafibrate ( n =3, 48 hours). E-F , CAOV3 cells were treated with ( E ) 5µM IKE or ( F ) 2.5µM JKE-1674, 2% ascites, and 200µM bezafibrate ( n =3, 48 hours). G-H , CAOV3 cells were treated with ( G ) 10µM erastin, 2% ascites, 200µM bezafibrate, 60µM fenofibrate, 500µM ciprofibrate, or ( H ) 250nM GW7647 ( n provided in panel, 48 hours). I , CAOV3 cells were transduced with a PPRE-luciferase reporter constructed and treated with 2% ascites in the presence or absence of 800µM bezafibrate. Luminescence was measured after 1mM D-luciferin addition ( n =3, 16 hours). J , The log-transformed changes in CAOV3 PPARA target DEGs after 10% ascites exposure ( n =3, 16 hours, adj. P =0.01). The target genes were determined via the PPARGene database ( http://www.ppargene.org/index.php ), which provides all verified PPARα target genes. K , ascites from 7-week-old NSG mice were collected after IVIS imaging. All ascites was pooled together and 8% was added to CAOV3 cells with or without 2.5µM JKE-1674 treatment to assess ferroptosis protection ( n =3). Cell viability tests were measured with the CellTiter-Glo® assay. All data represent mean ± s.d. Statistical significance was assessed using correlated-samples one-way (ANOVA), and multiple comparisons were adjusted using Holm-Šídák’s method. All statistical tests were two-tailed where applicable.

Journal: bioRxiv

Article Title: Ascitic fluid protects against ferroptosis and enables the peritoneal spread of ovarian cancer

doi: 10.1101/2024.11.23.624998

Figure Lengend Snippet: A , Cell viability was assessed in CAOV3 cells treated with 10µM erastin, 2% ascites, and 1mM bezafibrate (PPARα agonist), 0.8mM C-75 Trans (FASN inhibitor), 100µM Sulfo-N-succinimidyl oleate (SSO) (CD36 inhibitor), 50µM MF-438 (SCD1 inhibitor), and 80µM BMS-309403 (FABP4 inhibitor) ( n provided in panel, 48 hours). B-D , ( B ) TYKNU, ( C ) TOV21G, and ( D ) TOV112D cells were treated with 10µM erastin, 2% ascites, and 200µM ( B , D ) or 400µM ( C ) bezafibrate ( n =3, 48 hours). E-F , CAOV3 cells were treated with ( E ) 5µM IKE or ( F ) 2.5µM JKE-1674, 2% ascites, and 200µM bezafibrate ( n =3, 48 hours). G-H , CAOV3 cells were treated with ( G ) 10µM erastin, 2% ascites, 200µM bezafibrate, 60µM fenofibrate, 500µM ciprofibrate, or ( H ) 250nM GW7647 ( n provided in panel, 48 hours). I , CAOV3 cells were transduced with a PPRE-luciferase reporter constructed and treated with 2% ascites in the presence or absence of 800µM bezafibrate. Luminescence was measured after 1mM D-luciferin addition ( n =3, 16 hours). J , The log-transformed changes in CAOV3 PPARA target DEGs after 10% ascites exposure ( n =3, 16 hours, adj. P =0.01). The target genes were determined via the PPARGene database ( http://www.ppargene.org/index.php ), which provides all verified PPARα target genes. K , ascites from 7-week-old NSG mice were collected after IVIS imaging. All ascites was pooled together and 8% was added to CAOV3 cells with or without 2.5µM JKE-1674 treatment to assess ferroptosis protection ( n =3). Cell viability tests were measured with the CellTiter-Glo® assay. All data represent mean ± s.d. Statistical significance was assessed using correlated-samples one-way (ANOVA), and multiple comparisons were adjusted using Holm-Šídák’s method. All statistical tests were two-tailed where applicable.

Article Snippet: Ciprofibrate, fenofibrate, sulfosuccinimidyl oleate sodium (SSO) (HY-112847A), BMS-309403 (HY-101903), C-75 Trans (HY-12364A), MF-438 (HY-15822), and GW7647 (HY-13861) were purchased from MedChemExpress.

Techniques: Transduction, Luciferase, Construct, Transformation Assay, Imaging, Glo Assay, Two Tailed Test